AzTrials
AzTrials

Cesarean Section ComplicationsPhase 4NCT05264870

Norepinephrine in Caesarian Section

A Phase 4 study testing Norepinephrine in people with Cesarean Section Complications and Hemodynamic Instability, run by University Hospital, Antwerp at 1 site in Belgium.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Postspinal hypotension is a frequent maternal complication in caesarian delivery under neuraxial anesthesia which is most commonly treated with the administration of phenylephrine infusion. In this trial, postspinal hypotension will be treated with norepinephrine. Read more about this study

Who is it for?
Ages 18 years and older, women onlyHealthy volunteers can take part
What is being tested?
Norepinephrine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
11 participants
Where
1 siteBelgium
Study dates
9 Jun 2022to 27 Aug 2025
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • American Society of Anesthesiologists classification (ASA)1 and 2 patients
  • non-laboring and singleton pregnancy

Who cannot join

  • patients with cardiovascular comorbidities
  • any kind of cardiac and peripheral vascular disease or diabetes
  • history of coagulopathy
  • contra-indication to spinal anesthesia
  • allergic condition to vasopressors or local anesthetics
  • total body weight under 50kg or above 100kg
  • length under 150cm and over 180cm Body Mass Index (BM)I ≥ 32

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • Antwerp University Hospital

    Edegem, 2650

Other trials in Belgium

About this study

Official title: Norepinephrine as Hemodynamic Maintenance in Caesarian Delivery Under Spinal Anesthesia

Postspinal hypotension is a frequent maternal complication in caesarian delivery under neuraxial anesthesia which is most commonly treated with the administration of phenylephrine infusion. In this trial, postspinal hypotension will be treated with norepinephrine. The main objective is to examine the pharmacodynamic and biochemical effect of norepinephrine both on mother and newborn.

Read the detailed description

Patients scheduled for routine elective cesarean section under combined spinal epidural anesthesia (CSE)will be enrolled in this double-blind, randomized controlled trial, As standard of care for cesarean section procedure, a preoperative anesthetic consultation is performed. If the patient is eligible for enrollment, she will be provided with detailed information regarding the study and asked to sign Informed Consent. Participants are allocated to one of two groups: Group A will receive a CSE anesthesia with 7,5 milligrams (mg)hyperbaric Marcaine and 2,5 microgram (mcg)Sufentanil.

Group B will receive a CSE anesthesia as well with 10 mg hyperbaric Marcaine and 2,5 mcg Sufentanil. At the University Hospital Antwerp, Group A is standard of care for cesarean section. In case of insufficient pain relief an extra bolus of local anesthesia through the epidural catheter can be administered in both groups. In this trial we use a double blinding principle. Both the patient and the observant/study physician are fully blinded. To maintain blinding of the study, two anesthesiologists are involved in this trial. The first anesthesiologist will perform randomization by means of Redcap software and will prepare study medication according to allocation to group A or B just before start of spinal anesthesia. He /she is responsible for the placement of neuraxial block and the spinal epidural catheter. As part of routine care anesthesia an intravenous line with 500 milliliter (ml) Plasmalyte (minimal 20 Gauche catheter) will be established in both groups . Standard monitoring (blood pressure, Electrocardiogram and Oxygen saturation) will be applied.

A baseline systolic blood pressure will be measured as a mean of 3 consecutive measurements before start of CSE and is defined as baseline blood pressure.

Blood pressure will be measured every 1 minute. To maintain normotension during the procedure a continuous infusion of norepinephrine will be given at 15 milliliter/hour through the peripheral intravenous (IV)catheter in both groups. Therefore a solution of norepinephrine in a concentration of 10mcg/ml in a 50ml syringe is prepared and connected to the peripheral IV line, most proximal to the IV catheter. A combined spinal epidural puncture will be performed in the sitting position at the level of Lumbal (L)2-L3 or L3-L4 with a CSE needle set (18 Gauge Tuohy needle, 27 Gauge pencil point needle, 18 gauge catheter, Braun).

After placing the 18-gauge Tuohy needle in the epidural space, confirmed by loss of resistance with natriumchloride (NaCl) 0,9 percent (%), the spinal 27-gauge pencil point needle is advanced until it reaches the subarachnoidal space. Once the wright needle tip position is confirmed by back flow of cerebrospinal fluid (CSF), the local anesthetic solution will be injected in 15 seconds with the spinal needle orifice facing cephalad. Immediate after injection the epidural catheter will be inserted and placed at a distance of 5 cm beyond the Tuohy needle tip. Afterwards the patient is turned to the supine position A left lateral tilt (30%) will be applied to the operating table.

The Trendelenburg position of the table may be changed from -15 degree(°) to 15 ° table if necessary according to the anaesthetist in charge who is blinded for the appointed study group. In the unusual case of insufficient analgesia a single top-up dose of 5ml lidocaine 2% can be given through the epidural catheter. The bladder will be catheterized after spinal puncture. The start time of the recordings (T0) is the injection of the spinal anesthesia. At this moment we start the continuous infusion of norepinephrine. The anesthesiologist who performed the spinal anesthesia will leave the operating room and is replaced by a protocol trained second anesthesiologist to maintain blinding. The observer is always unaware of the appointed study group. He/she will titrate the continuous infusion of norepinephrine. In case of hypotension, defined as a decrease of 10% (more or equal) from baseline systolic arterial pressure, or an absolute value lower than( <) 100 mmHg, norepinephrine infusion will be increased with 2ml/hr each time with a maximum of 30ml/hr. Patients receive no extra volume loading besides a standard crystalloid infusion at a continuous rate of 80ml/u.

In case of hypertension, systolic blood pressure of more than 10% above baseline, the infusion will be lowered by 2ml/hr. Observation of vital parameters will be continued until safe delivery of the baby. Blood samples from the umbilical cord immediately after birth is part of standard of care.

With a non-inferiority margin of 0,05 we will need a sample size of 39 patients per group. Data will be collected using Redcap software to maximize transparency. Patient characteristics such as age and BMI will be compared with a two-sample T test to make sure that the two groups are equally representative.

All hemodynamic measurements such as heart rate and blood pressure will be compared with two-sample T-test. For ordinal variables such as Apgar scores and maternal nausea, a Wilcoxon-Mann Whitney test will be used. The occurrence of maternal vomiting will be compared using a Fisher's exact test.

Being tested
Norepinephrine

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • NorepinephrineDrug

    treatment of postspinal hypotension

  • NorepinephrineDrug

    treatment of postspinal hypotension

Study groups in NCT05264870
Study groupRoleWhat they receive
Group AActive comparatorcombined spinal epidural anesthesia (CSE) with 7,5mg hyperbaric Marcaine and 2,5mcg Sufentanil
Receives: Drug: Norepinephrine
Group BActive comparatorcombined spinal epidural anesthesia (CSE) anesthesia with 10mg hyperbaric Marcaine and 2,5mcg Sufentanil
Receives: Drug: Norepinephrine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. dose norepinephrine used in group A

    dose in microgram of norepinephrine used for treatment of hypotension in both arms

    Measured: from administration of spinal anesthesia until delivery of the newborn

  2. dose norepinephrine used in group B

    dose in microgram of norepinephrine used for treatment of hypotension in both arms

    Measured: from administration of spinal anesthesia until delivery of the newborn

Secondary outcomes (1)
  1. biochemical effect of norepinephrine on the newborn

    deviation of normal mean arterial pH 7.26 of the newborn

    Measured: bloodsample taken from umbilical cord at birth

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Mar 2022
  2. Study start9 Jun 2022
  3. Primary completion2 Mar 2023
  4. Study completion27 Aug 2025

Why it stopped: patient inclusion is too difficult

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Norepinephrine infusion is given for treatment of postspinal hypotension in treatment group A and B
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
11 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05264870
Sponsor's protocol ID
002105
Status last verified
Sep 2025
First submitted
22 Feb 2022
Last updated
10 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Norepinephrine in people with Cesarean Section Complications and Hemodynamic Instability, run by University Hospital, Antwerp at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 10 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: patient inclusion is too difficult). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

dose norepinephrine used in group A (time frame: from administration of spinal anesthesia until delivery of the newborn). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in